AJP - Regu Journal of Applied Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Regul Integr Comp Physiol 291: R692-R703, 2006. First published April 13, 2006; doi:10.1152/ajpregu.00086.2006
0363-6119/06 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
291/3/R692    most recent
00086.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LaBerge, J.
Right arrow Articles by Vizzard, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LaBerge, J.
Right arrow Articles by Vizzard, M. A.

INFLAMMATION AND CYTOKINES

Expression of corticotropin-releasing factor and CRF receptors in micturition pathways after cyclophosphamide-induced cystitis

Jennifer LaBerge,1 Susan E. Malley,1 Katarina Zvarova,1 and Margaret A. Vizzard1,2

Departments of 2Anatomy and Neurobiology and 1Neurology, University of Vermont College of Medicine, Burlington, Vermont

Submitted 1 February 2006 ; accepted in final form 4 April 2006


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Corticotropin-releasing factor (CRF) is a prominent neuropeptide involved in micturition reflexes, and different roles in these reflexes have been suggested. These studies examined the expression of CRF in the urinary bladder and lumbosacral sacral parasympathetic nucleus (SPN) in response to cyclophosphamide (CYP)-induced cystitis (4 h, 48 h, or chronic) in rats. The expression of CRF receptors, CRF1 and CRF2, was examined in urinary bladder from control and CYP-treated rats. Urinary bladder and lumbosacral spinal cord were harvested from rats killed by isoflurane (4%) and thoracotomy. CRF protein expression in whole urinary bladders significantly (P ≤ 0.01) increased with 48 h or chronic CYP treatment. CRF immunoreactivity (IR) was increased significantly (P ≤ 0.01) in the urothelium and SPN after CYP treatment. CRF IR nerve fibers increased in density in the suburothelial plexus and detrusor smooth muscle whole mounts with CYP-induced cystitis. CRF2 receptor transcript was expressed in the urothelium or detrusor smooth muscle, and CRF2 receptor expression increased in whole bladder with CYP-treatment, whereas no CRF1 receptor transcript was expressed in either urothelium or detrusor. Immunohistochemical studies demonstrated CRF2 IR in urinary bladder nerve fibers and urothelial cells from control animals, whereas no CRF1 IR was observed. These studies demonstrated changes in the expression of CRF in urinary bladder and SPN region with CYP-induced cystitis and CRF receptor (CRF2) expression in nerve fibers and urothelium in control rats. CRF may contribute to urinary bladder overactivity and altered sensory processing with CYP-induced cystitis.

inflammation; sacral parasympathetic nucleus; urothelium; enzyme-linked immunosorbet assay

THE CHEMICALLY (cyclophosphamide, CYP) induced bladder inflammation model is associated with alterations in neurochemical (57, 61), electrophysiological (66), organizational (62), and functional properties (14) of micturition pathways. These changes may be mediated by chemical mediators (e.g., neurotrophins, cytokines, neuropeptides) produced in the bladder, spinal cord, or dorsal root ganglia with cystitis (5, 27, 57, 59, 61).

Corticotropin-releasing factor (CRF) is of particular relevance in the rat, since it is present in descending projections from the pontine micturition center or more specifically from Barrington's nucleus to the sacral parasympathetic nucleus (SPN; see Refs. 30, 31, 49, 56). Historically, Barrington's nucleus has been viewed as the supraspinal switching center that regulates storage and elimination of urine (25, 33, 41). Recent studies have led to the suggestion that Barrington's nucleus may contain neurons that control a broad range of pelvic organ functions (28, 29, 34, 38, 55). CRF is prominently expressed in the descending pathway from Barrington's nucleus to the SPN in the lumbosacral spinal cord, and prominent CRF immunoreactivity (IR) is expressed in the SPN of adult rats (37, 53, 54). Our recent studies have demonstrated an age-dependent upregulation of CRF IR in the SPN region and specifically in association with preganglionic parasympathetic neurons (48). CRF-immunoreactive varicosities on or closely apposed to preganglionic parasympathetic cell bodies or proximal neurites also increased with postnatal age (48). We suggested that upregulation of CRF IR in bulbospinal projections to the SPN may contribute to mature voiding reflexes (48). Opposing roles for CRF in mature bladder function have been proposed (19, 34).

Patients with interstitial cystitis (IC), a painful, chronic urinary bladder inflammation syndrome, exhibit urinary frequency, urgency, and suprapubic and pelvic pain (35), and an involvement of C-fibers has been suggested (8). The overall hypothesis of this work is that CYP-induced cystitis results in changes in CRF expression in the urinary bladder or SPN region, contributing to bladder overactivity and changes in sensory processing. As initial steps in addressing this hypothesis, we determined: 1) CRF protein expression in the urinary bladder by enzyme-linked immunoassays (ELISAs) after CYP-induced cystitis of varying duration; 2) cellular expression of CRF and CRF receptors (CRF1, CRF2) in urinary bladder of control rats or after CYP-induced cystitis using immunohistochemistry with an emphasis on urothelial cell and nerve fiber expression; 3) CRF1 receptor and CRF2 receptor transcript expression in urinary bladder; 4) CRF2 receptor expression in whole urinary bladder with CYP-treatment using Western blotting techniques; and 5) intensity of CRF IR in the urothelium and SPN after CYP-induced cystitis using semiquantitative image analysis.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Adult female Wistar rats (150–250 g) were purchased from Charles River Canada (St. Constant, Canada). Chemicals used in these studies were purchased from Sigma ImmunoChemicals (St. Louis, MO). Primary antibodies for immunohistochemistry are described in Table 1. Secondary antibodies for immunohistochemistry were purchased from Jackson ImmunoResearch Laboratories (West Grove, PA; Table 1).


View this table:
[in this window]
[in a new window]
  		Table 1. Primary and secondary antibody sources and dilutions

 
CYP-induced Cystitis

Acute and chronic CYP-induced cystitis rat models were examined in these studies. For chronic CYP (Sigma)-induced cystitis studies, rats received drug injection (75 mg/kg ip) every 3rd day for 10 days. For acute CYP-induced cystitis studies, rats received a single injection (150 mg/kg ip) and survived for 4 or 48 h. Control rats received volume-matched injections of saline (0.9% ip) or no treatment. All injections were performed under isoflurane (2%) anesthesia. All experimental protocols involving animal use were approved by the University of Vermont Institutional Animal Care and Use Committee (no. 03–030; 06–014). Animal care was under the supervision of the University of Vermont's Office of Animal Care Management in accordance with the Association for Assessment and Accreditation of Laboratory Animal Care and National Institutes of Health guidelines. All efforts were made to minimize the potential for animal pain, stress, or distress.

Tissue Harvesting, Sample Preparation, and Assay

Procedures for tissue processing and ELISAs were identical to those described in detail previously. Adult rats were killed with isoflurane anesthesia (4%) and thoracotomy, and the bladder (n = 8–10 for each group) was rapidly dissected and weighed. Individual bladders were solubilized in T-PER Tissue Protein Extraction Reagent (1 g tissue/20 ml; Pierce, Rockford, IL) with Complete (protease inhibitor cocktail tablets; Roche Diagnostics). Bladder tissue was disrupted with a Polytron homogenizer and then centrifuged (10,000 revolutions/min for 5 min). Total protein was determined by the Coomassie Plus Protein Assay Reagent Kit (Pierce). The supernatant was used for CRF quantification using commercially available rat specific CRF ELISA kits (Peninsula Laboratories, member of the Bachem group, San Carlos, CA) in accordance with the manufacturer's instructions.

Rat CRF ELISA

Rabbit anti-rat CRF antibody was adsorbed to microtiter (R&D Systems, Minneapolis, MN) plates. After addition of the sample or standard solution, the second antibody (detection antibody) was applied. Sample and standard solutions were run in duplicate. This antibody complex was detected with a horseradish peroxidase-labeled immunoglobulin. Enzyme activity was quantified by the change in optical density, using tetramethyl benzidine as substrate. The CRF standard provided with this system generated linear standard curves from 0 to 10 ng/ml (r2 = 0.998, P ≤ 0.001). The absorbance values of standards and samples were corrected by subtraction of the background value (absorbance resulting from nonspecific binding). Samples were used undiluted to bring the absorbance values to the linear portion of the standard curve. No samples fell below the minimum detection limits of the assay. Curve fitting of standards and evaluation of CRF content of samples were performed using a least-squares fit.

Immunohistochemistry

Urinary bladder and lumbosacral spinal cord sections. Adult rats were killed as described in Tissue Harvesting, Sample Preparation, and Assay, and the bladder (n = 6 for each time point and control) was rapidly dissected and weighed. The spinal cord (cervical to sacral) was removed and pinned on a Sylgard dish and segmented. Spinal segments (L6–S1) were identified and placed in paraformaldehyde (4%) for 24 h. Spinal segments (L6–S1) were identified and then placed in sucrose (20%) for 24 h for cryoprotection and then sectioned (20 µm) in the transverse plane using a cryostat. Spinal cord segments were identified based on at least two criteria as follows: 1) the T13 dorsal root ganglion (DRG) exits after the last rib and 2) the L6 vertebra is the last moveable vertebrae followed by the fused sacral vertebrae. Segmentation was later confirmed by immunostaining the autonomic nucleus in the L6–S1 spinal segments with neuronal nitric oxide synthase (nNOS) IR (64). Our previous work (64) demonstrated that all nNOS IR cells in the rat SPN were retrogradely labeled from the major pelvic ganglion and therefore represented preganglionic parasympathetic neurons. Only spinal segments exhibiting nNOS IR in the autonomic nucleus were subsequently used in analysis, and all rats in the present study exhibited nNOS-immunoreactive cell bodies in the L6–S1 autonomic nucleus. A 1:4 series of spinal cord sections throughout the rostral-caudal extent of L6–S1 spinal segments were immunostained for CRF IR. Comparisons of CRF IR among different experimental groups were made from spinal cord sections matched to the same rostral-caudal location in the L6–S1 spinal segments. Sections of the bladder wall (20 µm) from control and experimental treatments (acute, intermediate, chronic CYP-induced cystitis) were examined for CRF IR. Groups of experimental animals were processed simultaneously to decrease the incidence of variation in staining and background that can occur between animals and on different processing days. Bladder sections were directly mounted on gelled (0.5%) microscope slides for on-slide processing, whereas spinal cord sections were processed free floating, as previously described (60). Briefly, all sections were incubated overnight at room temperature with primary antibody (Table 1) in 1% goat serum and 0.1 M PBS and then washed (3 x 10 min) with 0.1 M PBS, pH 7.4. The tissues were then incubated with Cy3-conjugated species-specific secondary antibodies (Table 1) for 2 h at room temperature in 0.1 M PBS, goat serum, and Triton X-100 (PBGT). For double labeling of CRF IR and nNOS-immunoreactive cells bodies in the autonomic nucleus in L6–S1, spinal cord sections were incubated in a cocktail of primary antibodies (Table 1) overnight as above and then incubated with a cocktail of species-specific secondary antibodies (Table 1) as above. To demonstrate CRF IR in neuronal fibers in the urinary bladder, urinary bladder sections were incubated with a cocktail of primary and secondary antibodies against CRF and the pan-neuronal marker protein gene product 9.5 (PGP9.5; Table 1). After being washed (3 x 10 min with 0.1 M PBS), the slides were coverslipped with Citifluor (Citifluor). Control sections incubated in the absence of primary or secondary antibody were also processed and evaluated for specificity or background staining levels. In the absence of primary antibody, no positive immunostaining was observed.

Whole Mount Bladder Preparation

Control and CYP-treated rats were killed as described in Tissue Harvesting, Sample Preparation, and Assay. The urinary bladder was dissected and placed in Krebs solution. The bladder was cut open along the midline and pinned out with maximum stretch to a Sylgard-coated dish. The bladder was incubated for 1.5 h at room temperature in cold fixative (2% paraformaldehyde + 0.2% picric acid), and urothelium removed as previously described (69). The urothelium has suburothelial structures associated with it, but we use the term urothelium in this paper to refer to both urothelium and suburothelial structures. Urothelium and bladder musculature were processed for CRF, CRF1, or CRF2 IR. Control (n = 6) and CYP-treated tissues (n = 6 for each group) tissues were processed for CRF1 IR or CRF2 IR, as described above (Table 1). Urinary bladder whole mounts were processed for CRF IR as described above.

Assessment of Positively Stained Urinary Bladder Regions

Staining observed in experimental tissue was compared with that observed from experiment-matched negative controls. Urinary bladder or lumbosacral spinal cord sections exhibiting IR that was greater than the background level observed in experiment-matched negative controls were considered positively stained. In this study, we have focused on CRF, CRF1, and CRF2 IR in the urothelium and bladder nerves in the detrusor and suburothelial plexus and SPN region.

Visualization and Quantitative Analysis of CRF IR in Urinary Bladder Sections, Whole Mounts, and SPN

Six to 10 urinary bladder or spinal cord sections from control and experimental groups were examined under an Olympus fluorescence photomicroscope (Optical Analysis, Nashua, NH) with a multiband filter set for visualization of the Cy3 fluorophore. Cy3 was visualized with a filter with an excitation range of 560–596 nm and an emission range from 610 to 655 nm. Grayscale images acquired in tiff format where imported into Meta Morph image analysis software (version 4.5r4; Universal Imaging, Downingtown, PA) as previously described (67). Images were calibrated for pixel size by applying a previously created calibration file to convert all measurements from pixels to square microns.

CRF IR in urothelium. The free-hand drawing tool was selected, and the urothelium was drawn and measured in total pixel area (see GoFig. 2, A, C, E, and G). A threshold within an intensity range of 100–250 grayscale values was applied to the region of interest (see Fig. 2, A, C, E, and G) in the least brightly stained condition first. The same threshold was subsequently used for all images. Average intensity was calculated within the outlined area. The average intensity represents the average value of all of the pixels above the threshold value. Percent CRF expression above threshold in the total area selected was then calculated and averaged for all samples from control (n = 10) and CYP-treated (n = 8 each) rats. Percentage CRF expression in CRF-treated rats was therefore expressed as a percentage of control.


Figure 1
View larger version (6K):
[in this window]
[in a new window]
  		Fig. 1. Changes in total urinary bladder corticotropin-releasing factor (CRF) as detected with immunoassays after different durations of cyclophosphamide (CYP) treatment. Significant increases in total urinary bladder CRF were detected after acute (48 h) or chronic (10 day) CYP treatment compared with control urinary bladder. *P ≤ 0.01.

 

Figure 2
View larger version (76K):
[in this window]
[in a new window]
  		Fig. 2. Semiquantitative analysis of CRF immunoreactivity (IR) in the urothelium after CYP-induced cystitis. The urothelium was outlined (green) and measured in total pixels area (A, C, E, and G). A threshold encompassing an intensity range of 100–250 grayscale values was applied to the region of interest (A, C, E, and G). The same threshold was subsequently used for all images. %CRF expression above threshold in the total area selected was then calculated. Grayscale versions of CRF IR in control urinary bladder (A), 4 (C) and 48 (E) h after CYP-treatment, or chronic CYP treatment (G) with the urothelium (U) outlined in green are shown. Images are thresholded, and little CRF (absence of yellow within the outlined region) is above threshold in control, 4 h, or chronic CYP-treated bladders compared with significant CRF IR that is above threshold after 48 h CYP treatment (E, presence of yellow within U). Fluorescence images of CRF expression in urinary bladder sections of control (B), 4-h (D), 48-h (F), and chronic (H) CYP-treated rats. For all images, exposure times were held constant, and all tissues were processed simultaneously. In control, 4-h, and chronic CYP-treated rats, little if any CRF expression was visible in the urothelium (B, D, and H), but some diffuse CRF IR was visible in suburothelial structures (SubU; D and F). CYP treatment (48 h, F) upregulated expression of CRF in the urothelium in all layers (apical, intermediate, and basal) of the U, and expression increased in the SubU. In normal or inflamed urinary bladder, expression of CRF in the detrusor smooth muscle was not evident. Differences in thickness of urothelium from control and CYP-treated bladders is attributed to edema, as previously demonstrated (58). Calibration bar represents 50 µm.

 
CRF IR in SPN. The same process was applied to CRF IR in the SPN region with two differences. First, a rectangle of fixed dimension (500 x 500 pixels) was placed over the SPN region in sections from all groups examined because, unlike the urothelium, the SPN could not accurately be outlined using the free-hand drawing tool (see GoFig. 4, A–D). Second, average intensity was calculated within the 500 x 500-pixel square. The average intensity represents the average value of all of the pixels above the threshold value. Percent CRF expression in the SPN above threshold in the area selected was then calculated and averaged for all samples from control (n = 10) and CYP-treated (n = 6 each) rats.


Figure 3
View larger version (5K):
[in this window]
[in a new window]
  		Fig. 3. Summary histogram of CRF expression in the urothelium (as shown in Fig. 1) with CYP treatment expressed as a percentage of control averaged for all bladders from all conditions examined (n = 8–10). *P ≤ 0.01.

 

Figure 4
View larger version (52K):
[in this window]
[in a new window]
  		Fig. 4. Fluorescence images of CRF IR surrounding neuronal nitric oxide synthase (nNOS) IR presumptive preganglionic parasympathetic neurons in the sacral parasympathetic nucleus (SPN) in adult (A–C) rat. CRF IR in the SPN region was punctate in nature (A and B). B and C: higher-power images of CRF IR in the SPN region (A, inset). CRF IR was in close apposition to nNOS IR presumptive preganglionic neurons (C, green cells, white arrows) in the SPN of adult rats. Some blood vessels in the spinal cord exhibit autofluorescence. Localization of CRF IR in close apposition to preganglionic parasympathetic neurons in the SPN was used as a means to ensure that CRF IR being analyzed (Figs. 5 and 6) was associated with the autonomic nucleus in L6–S1 spinal segments. DH, dorsal horn. Calibration bar represents 250 µm in A and 120 µm in B and C.

 
CRF IR nerve fibers. The density of CRF IR nerve fibers in the suburothelial plexus or detrusor was determined using a method modified from Brady et al. (7). Grayscale images acquired in tiff format where imported into Image J (1), and images were thresholded as described above. Images were acquired from the same area of detrusor in control and treated rats. A rectangle of fixed dimension (500 x 500 pixels) was placed on the section according to a random selection of x and y coordinates. This process was repeated seven times for each image of detrusor or urothelium. The average density of CRF IR nerve fibers was then calculated for all CRF IR nerve fibers in urinary bladders from control and CYP-treated rats (n = 8).

RNA Extraction, Reverse Transcription, and PCR

Urinary bladders were dissected from female rats; the urothelium and suburothelial structures were removed from the underlying bladder smooth muscle with the aid of fine forceps and a dissecting microscope, and all tissues were snap-frozen on dry ice before processing. In this study, use of the word urothelium refers to the urothelium and suburothelial structures. Total RNA from the different tissues was extracted using the STAT-60 total RNA/mRNA isolation reagent (Tel-Test "B," Friendswood, TX), as previously described (6). The quality and quantity of the resulting RNA were assessed with spectrometry at 260/280 nm, and 2 µg of total RNA from each sample were used to synthesize first-strand cDNA using SuperScript II RT with the SuperScript II Preamplification System (Invitrogen, Carlsbad, CA) in a 20-µl final reaction volume. After digestion with RNase H to remove residual RNA, the cDNA was amplified with 200 µM dNTP, 0.2 M primers, and 1.25 units AmpliTaq Gold DNA Polymerase with the following parameters: initial denaturation, 94°C, 5 min; denaturation, 94°C for 45 s; annealing, primer-specific annealing temperature for 30 s; extension, 72°C for 45 s (30–35 cycles); final extension, 72°C for 5 min. The oligonucleotide primers for CRF receptors, CRF1 and CRF2, were used as described by Porcher et al. (36; see Ref. Table 2). The amplified products were resolved on 2% agarose gels, stained with ethidium bromide, and visualized under ultraviolet illumination. cDNA synthesis in the absence of RNA template or RT or amplification without template, primers, or DNA polymerase were used as controls.


View this table:
[in this window]
[in a new window]
  		Table 2. Primer sequences for CRF1 and CRF2 receptors

 
Western Blotting for CRF2 Receptor IR in Urinary Bladder from Control and CYP-treated Rats

The bladder was harvested from control (n = 4) and CYP-treated (n = 4 each condition) rats and homogenized, and aliquots were removed for protein assay as described above. Samples (20 µg) were suspended in sample buffer for fractionation on Tris-glycine gels (Invitrogen) and subjected to SDS-PAGE. Proteins were transferred to nitrocellulose membranes, and efficiency of transfer was evaluated. Membranes were blocked overnight followed by rinsing in Tris-buffered saline plus 0.05% Tween. Membranes were then incubated in rabbit anti-CRF2 receptor (Table 1) overnight at 4°C. Washed membranes were incubated in horseradish peroxidase-conjugated donkey anti-goat IgG (Table 1) for 2 h at room temperature for enhanced chemiluminescence detection (Amersham, Piscataway, NJ). Blots were exposed to Biomax film (Kodak, Rochester, NY), and developed. The intensity of each band was analyzed (Un-Scan It; Silk Scientific, Orem, UT), and background intensities were subtracted. Western blotting of actin (Santa Cruz Biotechnology, Santa Cruz, CA) was used as a loading control. Antibody specificity was confirmed with absorption controls.

Statistics

All values are means ± SE. Comparisons of CRF protein concentration or CRF2 receptor expression in urinary bladder samples after acute (4 or 48 h) or chronic (10 days) CYP-induced cystitis were made using ANOVA. Percentage data from image analysis were arcsin transformed to meet the requirements of this statistical test. Animals, processed and analyzed on the same day, were tested as a block in the ANOVA. When F ratios exceeded the critical value (P ≤ 0.05), the Dunnett's post hoc test was used to compare the control means with each experimental mean.

Figure Preparation

Digital images were obtained using a CCD camera (MagnaFire SP; Optronics) and LG-3 frame grabber attached to an Olympus microscope (Optical Analysis). Exposure times were held constant when acquiring images from control and experimental animals processed and analyzed on the same day. Images were imported into Adobe Photoshop 7.0 (Adobe Systems, San Jose, CA) where groups of images were assembled and labeled.


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
CRF Protein Expression in Urinary Bladder with CYP-induced Cystitis

CRF protein expression in whole urinary bladders as determined by ELISAs significantly (P ≤ 0.01) increased (4.0-fold) with acute (48 h) CYP treatment and chronic CYP treatment (3.0-fold; Fig. 1). No change in CRF protein expression was observed 4 h after CYP treatment (Fig. 1).

CRF IR in Urothelium with CYP-Induced Cystitis

The expression of CRF IR was low in urothelium from urinary bladder sections from control (Fig. 2, A and B) and acute (4 h; Fig. 2, C and D) CYP treatment. Little if any CRF IR was present in suburothelial structures (Fig. 2, A and B) or detrusor smooth muscle of control rats. Acute (48 h; Fig. 2, E and F) CYP-induced cystitis increased (5.0-fold; P ≤ 0.01) CRF IR expression (Fig. 3) in the urothelium, and some diffuse CRF staining was observed in suburothelial structures. Similar to that observed for control rats, no CRF staining was observed in the detrusor smooth muscle with CYP treatment. No changes in CRF IR were observed in the urothelium with chronic CYP treatment (Fig. 2, G and H).

CRF Expression in Lumbosacral SPN

Distribution and general characteristics. As previously described (48) and confirmed in this study, CRF IR was expressed in distinct regions in lumbosacral spinal levels (L5–S1) in adult rats. CRF IR was most intense in the region of the SPN, but less intense CRF IR was also present in the medial and lateral dorsal horn (laminae I-II), dorsal commissure, and in a small fiber bundle extending ventrally from Lissauer's tract in lamina I along the lateral edge of the dorsal horn in the dorsal part of the SPN. CRF IR was largely absent from the ventral horn. CRF IR was expressed in nerve fibers in specific regions of the spinal cord and had a punctate staining quality (Fig. 4). In the SPN region, CRF IR was observed in close approximation to nNOS IR cells (presumptive preganglionic neurons; Fig. 4C). No CRF IR was observed in cell bodies in the spinal cord.

We focused the current analysis of CRF expression on the SPN in the lumbosacral spinal cord, since previous studies (48) from this laboratory and the current study have demonstrated the most abundant CRF IR in the adult SPN region compared with other spinal cord regions. We have confirmed that the CRF IR in the lateral horn of L6–S1 is associated with the autonomic nucleus by using segmentation protocols previously used and validated (6, 61, 64) and by also staining spinal cord sections for nNOS IR (48), a marker for preganglionic autonomic neurons (Fig. 4C). Consistent with our previous studies (48), dense CRF IR was present in the SPN region of the rat lumbosacral spinal cord (Figs. 4 and 5, A and B). With CYP-induced cystitis, the intensity of CRF IR in the SPN region was significantly (P ≤ 0.05) increased (2.0-fold; Fig. 6) after chronic CYP-treatment (Fig. 5, G and H).


Figure 5
View larger version (84K):
[in this window]
[in a new window]
  		Fig. 5. Semiquantitative analysis of CRF IR in the SPN of the L6–S1 spinal cord after CYP-induced cystitis. A box encompassing the SPN region (A, C, E, and G) was used consistently in all measurements from all conditions to outline the region of interest. A threshold within an intensity range of 100–250 grayscale values was applied to the region of interest (A, C, E, and G). The same threshold was subsequently used for all images. %CRF expression above threshold in the total area selected was then calculated. Grayscale versions of CRF IR in control SPN (A), 4 (D) and 48 (F) h after CYP treatment, or chronic CYP treatment (G) with the selected region outlined in green are shown. Images are thresholded, and the presence of yellow within the outlined region represents staining above threshold in control (A), 4-h (C), 48-h (E), or chronic CYP-treated (G) rats. Fluorescence images of CRF expression in SPN region of control (B), 4-h (D), 48-h (F), and chronic (H) CYP-treated rats. For all images, exposure times were held constant, and all tissues were processed simultaneously. With chronic CYP-induced cystitis, the intensity of CRF IR in the SPN region increased significantly (G and H). CC, central canal. Calibration bar represents 300 µm.

 

Figure 6
View larger version (6K):
[in this window]
[in a new window]
  		Fig. 6. Histogram of the intensity of CRF IR in the SPN region presented as a percentage of control for all tissues examined (n = 6–10) from the semiquantitative analysis described in Fig. 5. *P ≤ 0.01.

 
CRF Expression in Nerve Fibers from Whole Mounts of Urothelium/Suburothelium and Detrusor Smooth Muscle

To determine if CRF IR was present in the suburothelial nerve plexus, whole mount preparations of urinary bladder were prepared to aid in the visualization of the nerve plexus. In the detrusor whole mount preparation (Fig. 7A), very few CRF IR nerve fibers were observed in the detrusor from control rats. In contrast, CRF IR nerve fibers in the suburothelial plexus (Fig. 7C) in the urothelium/suburothelium whole mount preparation were more abundant in control rats. In contrast, with CYP-induced cystitis (48 h), the density of CRF IR nerve fibers in the detrusor (Fig. 7B) and suburothelial plexus (Fig. 7D) significantly (5.0-fold) increased. The density of CRF IR nerve fibers increased in the trigone and neck regions of the detrusor, whereas the CRF IR nerve fibers in the suburothelial plexus displayed a generalized increase in density. CRF IR nerve fibers in the detrusor or urothelium whole mounts exhibited colocalization with the pan-neuronal marker PGP9.5 (Fig. 7, E and F). In some detrusor whole mount samples, small, rounded cells without dendritric processes (presumptive mast cells) were observed to exhibit CRF and CRF2 receptor IR (data not shown). These cells show a similar morphology to mast cells previously described (14).


Figure 7
View larger version (107K):
[in this window]
[in a new window]
  		Fig. 7. Fluorescence photographs of CRF IR nerve fibers in the detrusor (A and B) or nerve fibers in the suburothelial plexus in whole mount preparations of the urothelium/suburothelium (C and D) in control (A and C) or CYP-treated (B and D) rats. Few CRF IR nerve fibers were observed in the detrusor from control rats (A). In contrast, CRF IR nerve fibers in the suburothelial plexus (C) in the urothelium/suburothelium whole mount preparation were more abundant in control rats. With CYP-induced cystitis (48 h), the density of CRF IR nerve fibers in the detrusor (B) and suburothelial plexus (D) increased. CRF IR nerve fibers in the urothelium or detrusor whole mount preparations colocalized with the pan-neuronal marker protein gene product 9.5 (PGP9.5; arrows; E). CRF IR nerve fibers colocalized with PGP9.5 IR in the same urothelium whole mount (E). F: merged image of D and E that demonstrates complete overlap between CRF and PGP immunostaining in the suburothelial plexus of the urothelium. Several examples of colabeled nerve fibers are indicated (D–F, arrows). Calibration bar represents 80 µm.

 
CRF1 and CRF2 in Control Whole Mounts of Urothelium/suburothelium or Detrusor Smooth Muscle

We examined the distribution of CRF1 receptor and CRF2 receptor in whole mounts of urothelium/suburothelium and detrusor smooth muscle. CRF2 receptor IR was observed in urothelial cells (Fig. 8A) in the bladder dome and in the suburothelial nerve plexus near the urinary bladder neck (Fig. 8B). No CRF2 receptor IR nerve fibers were observed in the suburothelial nerve plexus in the bladder dome. CRF2 receptor IR was also present in single nerve fibers and nerve trunks scattered throughout the detrusor smooth muscle (Fig. 8C). In contrast, no CRF1 receptor IR staining was observed in any region of the urinary bladder examined.


Figure 8
View larger version (39K):
[in this window]
[in a new window]
  		Fig. 8. CRF2 receptor IR in the urinary bladder of control rats. CRF2 receptor IR was observed in urothelial cells (A) in the bladder dome and in the suburothelial nerve plexus near the urinary bladder neck (B). No CRF2 receptor IR nerve fibers were observed in the suburothelial nerve plexus in the bladder dome. CRF2 receptor IR was also present in single nerve fibers (arrows) and nerve trunks (arrowheads) scattered throughout the detrusor smooth muscle (C). Calibration bar represents 60 µm.

 
CRF1 and CRF2 Transcript Expression in Control Urothelium/suburothelium or Detrusor Smooth Muscle

From RT-PCR analyses, both urinary bladder detrusor smooth muscle and urothelium demonstrated similar patterns of CRF2 receptor transcript expression (Fig. 9). In contrast, neither detrusor smooth muscle nor urothelium/suburothelium expressed CRF1 receptor transcript expression (Fig. 9), in agreement with the immunohistochemistry studies described above.


Figure 9
View larger version (26K):
[in this window]
[in a new window]
  		Fig. 9. Lower urinary tract tissues express CRF2 receptor transcript. The urinary bladder smooth muscle and urothelium/suburothelium express CRF2 receptor transcript. In contrast, these tissues do not express CRF1 receptor transcript.

 
Upregulation of CRF2 Receptor Expression in Whole Urinary Bladder from CYP-treated Rats

Western blotting of whole urinary bladder from control and CYP-treated rats demonstrated significant (P ≤ 0.05) upregulation of CRF2 receptor expression 48 h after CYP treatment (Fig. 10). CRF2 receptor expression tended to increase with CYP treatment with 4-h and chronic CYP treatment; however, this trend was not significant (Fig. 10).


Figure 10
View larger version (29K):
[in this window]
[in a new window]
  		Fig. 10. A: representative example of a Western blot of whole urinary bladder (20 µg) for CRF2 receptor expression in control rats and those treated with CYP for varying duration. Actin staining was used as a loading control. B: histogram of relative CRF2 receptor band density in all groups examined normalized to actin staining. CRF2 receptor expression in urinary bladder is significantly increased with 48-h CYP treatment. OD, optical density. *P ≤ 0.05.

 

   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
We demonstrate several novel findings with respect to CRF expression in lower urinary tract (LUT) tissues and its plasticity with CYP-induced cystitis. CRF protein expression in whole urinary bladders significantly increased with CYP treatment (48 h or chronic). CRF IR was increased significantly in the urothelium and SPN after CYP treatment, although the time course of this upregulation was tissue dependent. The density of CRF IR nerve fibers increased in the suburothelial plexus and detrusor with CYP-induced cystitis. CRF2 receptor transcript was expressed in the urothelium or detrusor smooth muscle in control rats, and CRF2 receptor expression was upregulated significantly with CYP treatment, whereas no CRF1 receptor transcript was expressed in either tissue examined. CRF2 receptor IR was present in urinary bladder nerve fibers and urothelial cells from control animals. Immunohistochemical studies confirmed the selective distribution of CRF2 receptor to LUT tissues. The present studies demonstrated the plasticity in CRF and CRF2 receptor expression in urinary bladder and SPN with CYP-induced cystitis.

IC is a chronic inflammatory bladder disease syndrome characterized by urinary frequency, urgency, and suprapubic and pelvic pain (10, 35). Although the etiology and pathogenesis of IC are unknown, numerous theories, including infection, autoimmune disorder, toxic urinary agents, deficiency in bladder wall lining, and neurogenic causes, have been proposed (10, 13, 17, 35, 40). Alterations in peripheral bladder afferent (sensory)/efferent (autonomic and motor) and central interneuronal pathway functions as well as changes in the urinary bladder may underlie detrusor overactivity that accompany CYP-induced cystitis. Pain associated with IC may involve an alteration of visceral sensation/bladder sensory physiology. These changes may be mediated, in part, by inflammatory changes in the urinary bladder.

Chemical cystitis was induced in female Wistar rats by CYP that is metabolized to acrolein, an irritant eliminated in the urine (9, 24). Within the urinary tract, the urinary bladder is the organ most affected by the toxic actions of CYP because of its reservoir function and the longer exposure to the toxic metabolite acrolein (9, 24, 47). The most common urological complication associated with CYP treatment in humans is cystitis, with or without hemorrhage (9, 24, 47, 65). Gross histological findings from the current study and previous studies (16, 63, 66) of animals treated with CYP demonstrate extensive regions of urothelial erosion, ulcerations, edema, and associated increases in bladder weight and petechial hemorrhages. Recent studies (58) have also demonstrated extensive monocyte/macrophage infiltration in the inflamed urinary bladder and a significant increase in myeloperoxidase activity. Our previous studies (14, 27, 58, 59) have demonstrated that chronic CYP treatment generates a more pronounced inflammatory response compared with acute (4 or 48 h) CYP treatment evidenced by histological observations and diffuse inflammatory cell infiltration and increased expression of PGE2 and cyclooxygenase-2 (COX-2) in the urinary bladder. Previous studies have suggested that mast cells in the inflamed urinary bladder are the cellular source of COX-2 (14). In contrast, increases in PGD2 in the urinary bladder were biphasic, occurring with both acute (4 h) and chronic CYP treatment but not acute (48 h) treatment (14). Animal studies have also indicated that CYP treatment (acute treatment) in the rat induces increased frequency of voiding in awake rats and urinary bladder hyperreflexia in anesthetized rats (14, 21–23, 26), and these changes are maintained with acute (48 h) and chronic CYP treatment. Thus CYP treatment represents a noxious, chemical irritation of the urinary bladder that also induces bladder overactivity. Repeated intraperitoneal injection of rats with CYP results in a progressive inflammatory condition with sustained bladder overactivity.

Previous studies have demonstrated that a number of neurotrophic factors (15, 59), neuropeptides (6, 57), and cytokines (27, 67) are upregulated in the urinary bladder after CYP-induced cystitis. Subtractive techniques to block these factors improve bladder function and reduce pain-related behaviors (6, 15). We believe that this study is the first to demonstrate upregulation of CRF in the urinary bladder and specifically in the urothelium and bladder nerve fibers after CYP-induced cystitis. Previous gene profiling studies have demonstrated upregulation of CRF receptor in the urinary bladder in murine models of cystitis (39). We extend these studies by demonstrating upregulation of CRF in both acute and chronic CYP-induced cystitis as well as by demonstration of increased CRF expression in specific urinary bladder tissues (urothelium and nerve fibers). Urothelial cells share a number of similarities with sensory neurons, and the urothelium has been suggested (2–4) to have "neuronal-like" properties. Urothelial cells express a number of receptors and ion channels similar to those found in sensory neurons (4, 32). The effectiveness of capsaicin treatment in depleting CRF IR from the dorsal horn has been taken as evidence that CRF originates from some primary afferent cells in the DRG (42). We have previously (48) demonstrated that the majority of CRF IR in the SPN in the adult rat originates from supraspinal sites. In contrast, CRF IR in the dorsal horn was still evident and may indicate that other sources (i.e., afferent cells in the DRG) contribute to the dorsal horn staining as well, or perhaps, exclusively (48). However, Puder and Pakpa (37) indicate that no CRF IR DRG cells have been identified. Thus CRF may add to the ever-growing list of similarities between urothelial cells and DRG cells. Changes in CRF IR in the SPN of the lumbosacral spinal cord were also demonstrated with CYP-induced cystitis. It is not known if these changes reflect changes in CRF IR in the descending limb of the micturition reflex or changes in afferent projections from DRG cells; however, it is demonstrated that changes in central expression of the neuropeptide occur with CYP-induced cystitis. Central changes in CRF expression are consistent with our previous demonstrations with calcitonin gene-related peptide (57), substance P (57), pituitary adenylate cyclase-activating polypeptide (6), and galanin (68).

Although increases in CRF expression or protein content were demonstrated in the urinary bladder and SPN region of the lumbosacral spinal cord, the time course of this upregulation was different and may reflect different roles for CRF in different parts of the micturition reflex. Increased CRF protein expression in the whole urinary bladder was demonstrated after 48 h or chronic CYP treatment, whereas CRF IR was increased significantly in the urothelium and suburothelial nerve fibers 48 h after CYP treatment. Detrusor smooth muscle from control or CYP-treated rats largely lacked CRF IR, so differences between the ELISA results and the immunohistochemistry and subsequent semiquantitative analysis may be because of upregulation of CRF in the suburothelial region that did demonstrate CRF IR or may also reflect differences in the sensitivity between these two techniques and the use of different antibodies against CRF. In contrast, increased CRF IR in the SPN region of the lumbosacral spinal cord was only observed with chronic CYP treatment. Comparisons of CRF IR in the SPN region were made among experimental groups with spinal cord sections matched with respect to rostral-caudal location in the L6–S1 spinal segments. It should also be noted that CYP-induced cystitis and cystitis induced by other chemical irritants is associated with central and peripheral upregulation of a number of neuropeptides (6, 57), cytokines (27, 67), and neurotrophic (15, 59) factors that may all contribute to altered sensory processing and bladder overactivity. It is not possible with this present study that focuses solely on CRF and CRF receptor distribution, expression, and plasticity with CYP-induced cystitis, without examining the functional contribution of CRF to LUT reflexes, to attribute a definitive role for CRF in the acute or chronic stages of CYP-induced cystitis. Bladder inflammation can have both acute and chronic stages such as observed in IC, and these stages may induce expression of genes and protein that underlie inflammation, edema, tissue degradation, and tissue remodeling, repair, and adaptive strategies (39). Expression of CRF after acute or chronic CYP-induced cystitis in LUT tissues suggests diverse roles for CRF that remain to be fully elucidated.

The reasons for the differences in the time course of the expression of CRF in the urinary bladder, bladder nerve fibers, and SPN region are not known but may reflect tissue-specific roles in acute and chronic bladder inflammation stages. If one compares CRF expression changes in these tissues using only the immunohistochemistry data and semiquantitative analyses, one observes significant upregulation of CRF IR in the urothelium and suburothelial nerve fibers 48 h after CYP treatment. In contrast, upregulation of CRF IR in the SPN region of the lumbosacral spinal cord was only observed after chronic CYP treatment. Differences may reflect a role for CRF in long-term remodeling of the spinal cord with chronic bladder inflammation and/or may also suggest that CRF is upregulated secondary to the local production of or retrograde transport of target tissue-derived neurotrophic factors (59).

Neurotrophic factors expressed in the inflamed urinary bladder may also contribute to CRF upregulation. Previous studies from several laboratories have suggested that neurotrophic factor expression in the urinary bladder may underlie the changes in the neurochemical (57, 61) and electrical (66) phenotype of bladder afferent neurons after urinary bladder dysfunction. Recent experiments from several laboratories, including our own, have demonstrated the influence of target organ-neuron interactions in the adult animal (11, 15, 43–46, 51, 52). Studies from our laboratory have demonstrated that CYP-induced cystitis alters the expression of nerve growth factor (NGF) and NGF mRNA in the urinary bladder and in major pelvic ganglia (59). A number of other neurotrophic factors, including brain-derived neurotrophic factor, glial-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4, are also upregulated in the inflamed urinary bladder (32, 59).

Conflicting roles for CRF in micturition reflex pathways have been described previously. CRF is expressed prominently in the descending pathway from Barrington's nucleus to the SPN in the lumbosacral spinal cord, and prominent CRF IR is expressed in the SPN of adult rats (37, 53, 54). Intrathecal administration of CRF decreases the amplitude of bladder contractions induced by electrical stimulation of Barrington's nucleus (34), suggesting that CRF in descending projections from Barrington's nucleus to the SPN is inhibitory. On the other hand, recent studies now demonstrate that intrathecal or systemic CRF induces bladder overactivity (19, 20). Different putative roles for CRF in these studies may be related to the use of halothane-anesthetized (34) or conscious (19, 20) rats for functional studies. Klausner et al. (19, 20) suggest that CRF's role in voiding function and dysfunction is related to a central stress response and may underlie bladder overactivity in the clinical syndrome of IC. On the other hand, Pavcovich et al. (34) suggest that CRF's role in the voiding reflex is in maintaining continence. Our previous study (48) that described an age-dependent upregulation of CRF IR in the SPN is more consistent with a role in maintaining continence, since the mature voiding reflex must alternate between two modes of operation, voiding, and storage. However, the present studies demonstrate time- and tissue-dependent upregulation of CRF in bladder reflex pathways with CYP-induced cystitis, but whether or not this upregulation has any functional significance remains to be determined. It may be the case that CRF plays different roles in bladder function during development and inflammatory conditions and may be dependent on the presence of mast cells, as previously suggested (39, 50). Clearly, additional functional studies are needed to define the role of CRF in normal and inflamed states.

This study also has the first demonstration of CRF2 receptor transcript in the urinary bladder (urothelium/suburothelium or detrusor) of control rats and CRF2 receptor IR in urothelial cells and nerve fibers located both in the detrusor and suburothelial plexus. In contrast, neither CRF1 receptor transcript nor CRF1 receptor IR was expressed in bladder from control rats. In the small intestine, CRF1–2 receptors were distributed within the neuronal elements of both nerve varicosities and nerve cell bodies in addition to epithelial cells (36). The CRF2 receptor distribution in the small intestine (36) is consistent with the observations in the present study. However, CRF1–2 receptors were also located in the tunica muscularis of the small intestine (36), whereas no CRF1 receptor expression was observed in the detrusor smooth muscle in the present study. Western blotting of whole urinary bladders from CYP-treated rats (48 h) demonstrated a significant upregulation of CRF2 receptor expression compared with control urinary bladder. Previous studies have demonstrated modulation of CRF2 receptor transcript in the rat cardiovascular system after lipopolysaccharide or glucocorticoid administration (18). It is worth noting that CRF is probably not the natural ligand for CRF2 receptor, and a number of studies argue that that natural ligand for CRF2 receptor is urocortin (18). Interestingly, a recent report suggests that urocortin may be an endogenous anti-inflammatory factor and demonstrates that treatment with urocortin decreases the severity of inflammatory colitis in a murine model (12). These studies clearly have implications for IC. Whereas CRF may not be a natural ligand for CRF2 receptor (18), recent studies suggest that the peptide cocaine-and-amphetamine regulated transcript (CART) protein may function through CRF receptors. Recent studies (69, 70) from this laboratory have demonstrated CART expression in intramural neurons and nerve fibers of the urinary bladder during development and in adult rats. Furthermore, CART peptide also facilitates detrusor contractility (71).

In conclusion, these studies have demonstrated significant time- and tissue-dependent changes in CRF expression in LUT tissues after CYP-induced cystitis (acute and chronic). This study has demonstrated that inflammation of the urinary bladder induces changes in bladder CRF expression in the urothelium and in urinary bladder nerve fibers with acute (48 h) CYP treatment. Central changes in CRF expression in the SPN of the lumbosacral spinal cord were also observed with chronic CYP treatment. The CRF2 receptor is expressed in urinary bladder and specifically in the urothelium and bladder nerve fibers, and its expression is increased in whole urinary bladder with CYP-induced cystitis. In contrast, no CRF1 receptor transcript or IR was observed in LUT tissues. This study demonstrates that CRF and CRF2 receptor expression is altered in LUT tissues with CYP-induced cystitis and adds to a growing number of neuropeptides, cytokines, and neurotrophic factors with altered expression in LUT tissues with CYP-induced cystitis. The interactions among these neuroactive compounds in the context of acute and chronic bladder inflammation remain to be determined. Ongoing studies are determining the functional contribution of CRF and urocortin to LUT function after cystitis using CRF1 and CRF2 receptor antagonists.


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This work was funded by National Institutes of Health Grants DK-051369, DK-060481, DK-065989, and NS-040796.


   ACKNOWLEDGMENTS
 
J. LaBerge was supported, in part, by a Neuroscience Summer Undergraduate Research Fellowship from the University of Vermont, Departments of Anatomy and Neurobiology and Neurology.


   FOOTNOTES
 

Address for reprint requests and other correspondence: M. A. Vizzard, Dept. of Neurology, Univ. of Vermont College of Medicine, D411 Given Bldg., Burlington, VT 05405 (e-mail: margaret.vizzard{at}uvm.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Abramoff MD, Magelhaes PJ, and Ram SJ. Image processing with ImageJ. Biophotonics Internl 11: 36–42, 2004.
  2. Birder LA. More than just a barrier: urothelium as a drug target for urinary bladder pain. Am J Physiol Renal Physiol 289: F489–F495, 2005.[Abstract/Free Full Text]
  3. Birder LA. Role of the urothelium in urinary bladder dysfunction following spinal cord injury. Prog Brain Res 152: 135–146, 2005.
  4. Birder LA, Kanai AJ, deGroat WC, Kiss S, Nealen ML, Burke NE, Dineley KE, Watkins S, Reynolds IJ, and Caterina MJ. Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells. Proc Natl Acad Sci USA 98: 13396–13401, 2001.[Free Full Text]
  5. Braas KM, May V, Zvara P, Nausch B, Kliment J, Dunleavy JD, and Nelson MT. Role for pituitary adenylate cyclase activating polypeptide (PACAP) in cystitis-induced plasticity of micturition reflexes (Abstract). Reg Peptides 130: 157, 2005.[CrossRef]
  6. Braas KM, May V, Zvara P, Nausch B, Kliment J, Dunleavy JD, Nelson MT, and Vizzard MA. Role for pituitary adenylate cyclase activating polypeptide (PACAP) in cystitis-induced plasticity of micturition reflexes. Am J Physiol Regul Integr Comp Physiol 290: R951–R962, 2006.[Abstract/Free Full Text]
  7. Brady CM, Apostolidis AN, Harper M, Yiangou Y, Beckett A, Jacques TS, Freeman A, Scaravilli F, Fowler CJ, and Anand P. Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int 93: 770–776, 2004.[CrossRef][Web of Science][Medline]
  8. Chancellor MB and Yoshimura N. Treatment of interstitial cystitis. Urology 63: 85–92, 2004.[CrossRef][Web of Science][Medline]
  9. Cox PJ. Cyclophosphamide cystitis–identification of acrolein as the causative agent (Abstract). Biochem Pharmacol 28: 2045, 1979.[CrossRef][Web of Science][Medline]
  10. Driscoll A and Teichman JMH. How do patients with interstitial cystitis present? J Urol 166: 2118–2120, 2001.[CrossRef][Web of Science][Medline]
  11. Dupont MC, Spitsbergen JM, Kim KB, Tuttle JB, and Steers WD. Histological and neurotrophic changes triggered by varying models of bladder inflammation. J Urol 166: 1111–1118, 2001.[CrossRef][Web of Science][Medline]
  12. Gonzalez-Rey E, Fernandez-Martin A, Chorny A, and Delgado M. Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease. Gut 55: 824–832, 2006.[Abstract/Free Full Text]
  13. Ho N, Koziol JA, and Parsons CL. Epidemiology of interstitial cystitis. In: Interstitial Cystitis, edited by Sant GR. Philadelphia, PA: Lippincott-Raven, 1997, p. 9–16.
  14. Hu VY, Malley S, Dattilio A, Folsom JB, Zvara P, and Vizzard MA. COX-2 and prostanoid expression in micturition pathways after cyclophosphamide-induced cystitis in the rat. Am J Physiol Regul Integr Comp Physiol 284: R574–R585, 2003.[Abstract/Free Full Text]
  15. Hu VY, Zvara P, Dattilio A, Redman TL, Allen SJ, Dawbarn D, Stroemer RP, and Vizzard MA. Decrease in bladder overactivity with REN1820 in rats with cyclophosphamide induced cystitis. J Urol 173: 1016–1021, 2005.[CrossRef][Web of Science][Medline]
  16. Jennings LJ and Vizzard MA. Cyclophosphamide-induced inflammation of the urinary bladder alters electrical properties of small diameter afferent neurons from dorsal root ganglia (Abstract). FASEB J 13: A57, 1999.
  17. Johansson SL, Ogawa K, and Fall M. The pathology of interstitial cystitis. In: Interstitial Cystitis, edited by Sant GR. Philadelphia, PA: Lippincott-Raven, 1997, p. 143–152.
  18. Kageyama K, Gaudriault GE, Bradbury MJ, and Vale WW. Regulation of corticotropin-releasing factor receptor type 2 beta messenger ribonucleic acid in the rat cardiovascular system by urocortin, glucocorticoids, and cytokines. Endocrinology 141: 2285–2293, 2000.[Abstract/Free Full Text]
  19. Klausner AP and Steers WD. Corticotropin releasing factor: a mediator of emotional influences on bladder function. J Urol 172: 2570–2573, 2004.[CrossRef][Medline]
  20. Klausner AP, Streng T, Na YG, Raju J, Batts TW, Tuttle JB, Andersson KE, and Steers WD. The role of corticotropin releasing factor and its antagonist, astressin, on micturition in the rat. Auton Neurosci 123: 26–35, 2005.[CrossRef][Web of Science][Medline]
  21. Koss LG and Lavin P. Effects of a single dose of cyclophosphamide on various organs in the rat. II. Response of urinary bladder epithelium according to strain and sex. J Natl Cancer Inst 44: 1195–1200, 1970.[Web of Science][Medline]
  22. Lantéri-Minet M, Bon K, de Pommery J, Michiels JF, and Menétrey D. Cyclophosphamide cystitis as a model of visceral pain in rats: model elaboration and spinal structures involves as revealed by the expression of c-Fos and Krox-24 proteins. Exp Brain Res 105: 220–232, 1995.[Web of Science][Medline]
  23. Lecci A, Giulani S, Santiciolo P, and Maggi CA. Involvement of spinal tachykinin NK1 and NK2 receptors in detrusor hyperreflexia during chemical cystitis in anaesthetized rats. Eur J Pharmacol 259: 129–135, 1994.[CrossRef][Web of Science][Medline]
  24. Levine LA and Richie JP. Urological complications of cyclophosphamide. J Urol 141: 1063–1069, 1989.[Web of Science][Medline]
  25. Loewy AD, Saper CB, and Baker RP. Descending projections from the pontine micturition center. Brain Res 172: 533–538, 1979.[CrossRef][Web of Science][Medline]
  26. Maggi CA, Lecci A, Santiciolo P, Del Biance E, and Giuliani S. Cyclophosphamide cystitis in rats: involvement of capsaicin-sensitive primary afferents. J Auton Nerv Syst 38: 201–208, 1992.[CrossRef][Web of Science][Medline]
  27. Malley SE and Vizzard MA. Changes in urinary bladder cytokine mRNA and protein after cyclophosphamide-induced cystitis. Physiol Genom 9: 5–13, 2002.[Abstract/Free Full Text]
  28. Marson L. Identification of central nervous system neurons that innervate the bladder body, bladder base, or external urethral sphincter of female rats: a transneuronal tracing study using pseudorabies virus. J Comp Neurol 389: 584–602, 1997.[CrossRef][Web of Science][Medline]
  29. Marson L, Platt KB, and McKenna KE. Central nervous system innervation of the penis as revealed by the transneuronal transport of pseudorabies virus. Neuroscience 55: 263–280, 1993.[CrossRef][Web of Science][Medline]
  30. Merchenthaler I. Corticotropin releasing factor (CRF)-like immunoreactivity in the rat central nervous system. Extrahypothalamic distribution. Peptides 5: 53–69, 1984.[Web of Science][Medline]
  31. Merchenthaler I, Vigh S, Petrusz P, and Schally AV. Immunocytochemical localization of corticotropin releasing factor (CRF) in the rat brain. Am J Anat 165: 385–396, 1982.[CrossRef][Web of Science][Medline]
  32. Murray E, Malley SE, Qiao LY, Hu VY, and Vizzard MA. Cyclophosphamide induced cystitis alters neurotrophin and receptor tyrosine kinase expression in pelvic Ganglia and bladder. J Urol 172: 2434–2439, 2004.[CrossRef][Web of Science][Medline]
  33. Noto H, Roppolo JR, Steers WD, and de Groat WC. Excitatory and inhibitory influences on bladder activity elicited by electrical stimulation in the pontine micturition center in the rat. Brain Res 492: 99–115, 1989.[CrossRef][Web of Science][Medline]
  34. Pavcovich LA, Yang M, Miselis RR, and Valentino RJ. Novel role for the pontine micturition center, Barrington's nucleus: evidence for coordination of colonic and forebrain activity. Brain Res 784: 355–361, 1998.[CrossRef][Web of Science][Medline]
  35. Petrone RL, Agha AH, Roy JB, and Hurst RE. Urodynamic findings in patients with interstitial cystitis (Abstract). J Urol 153: 290A, 1995.
  36. Porcher C, Juhem A, Peinnequin A, Sinniger V, and Bonaz B. Expression and effects of metabotropic CRF1 and CRF2 receptors in rat small intestine. Am J Physiol Gastrointest Liver Physiol 288: G1091–G1103, 2005.[Abstract/Free Full Text]
  37. Puder BA and Papka RE. Distribution and origin of corticotropin-releasing factor-immunoreactive axons in the female rat lumbosacral spinal cord. J Neurosci Res 66: 1217–1225, 2001.[CrossRef][Web of Science][Medline]
  38. Rouzade-Dominguez ML, Pernar L, Beck S, and Valentino RJ. Convergent responses of Barrington's nucleus neurons to pelvic visceral stimuli in the rat: a juxtacellular labelling study. Eur J Neurosci 18: 3325–3334, 2003.[CrossRef][Web of Science][Medline]
  39. Saban MR, Nguyen NB, Hammond TG, and Saban R. Gene expression profiling of mouse bladder inflammatory responses to LPS, substance P, and antigen-stimulation. Am J Path 160: 2095–2110, 2002.[Abstract/Free Full Text]
  40. Sant G and Hanno PM. Interstitial cystitis: current issues and controversies in diagnosis (Abstract). Urology 57: 82, 2001.[CrossRef][Web of Science][Medline]
  41. Satoh K, Shimizu N, Tohyama M, and Maeda T. Localization of the micturition reflex center at dorsolateral pontine tegmentum of the rat. Neurosci Lett 8: 27–33, 1978.
  42. Skofitsch G, Hamill GS, and Jacobowitz DM. Capsaicin depletes corticotropin-releasing factor-like immunoreactive neurons in the rat spinal cord and medulla oblongata. Neuroendocrinology 38: 514–517, 1984.[CrossRef][Web of Science][Medline]
  43. Steers WD, Ciambotti J, Etzel B, Erdman S, and de Groat WC. Alterations in afferent pathways from the urinary bladder of the rat in response to partial urethral obstruction. J Comp Neurol 310: 1–10, 1991.[CrossRef][Web of Science][Medline]
  44. Steers WD, Creedon DJ, and Tuttle JB. Immunity to nerve growth factor prevents afferent plasticity following urinary bladder hypertrophy. J Urol 155: 379–385, 1996.[CrossRef][Web of Science][Medline]
  45. Steers WD and de Groat WC. Effect of bladder outlet obstruction on micturition reflex pathways in the rat. J Urol 140: 864–871, 1988.[Web of Science][Medline]
  46. Steers WD, Kolbeck S, Creedon D, and Tuttle JB. Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. J Clin Invest 88: 1709–1715, 1991.[Web of Science][Medline]
  47. Stillwell TJ and Benson RC. Cyclophosphamide-induced cystitis. A review of 100 patients. Cancer 61: 451–457, 1988.[CrossRef][Web of Science][Medline]
  48. Studeny S and Vizzard MA. Corticotropin-releasing factor (CRF) expression in postnatal and adult rat sacral parasympathetic nucleus (SPN). Cell Tissue Res 322: 339–352, 2005.[CrossRef][Web of Science][Medline]
  49. Suzuki T, Kawatani M, Erdman S, and de Groat WC. Role of CRF and 5-HT in central pathways controlling micturition in the rat (Abstract). Soc Neurosci Abstr 16: 1064, 1990.
  50. Theoharides TC, Singh LK, Boucher W, Pang X, Letourneau R, Webster E, and Chrousos G. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology 139: 403–413, 1998.[Abstract/Free Full Text]
  51. Tuttle JB, Mackey T, and Steers WD. NGF, bFGF and CNTF increase survival of mejor pelvic ganglion neurons cultured from the adult rat. Neurosci Lett 173: 94–98, 1994.[CrossRef][Web of Science][Medline]
  52. Tuttle JB, Steers WD, Albo M, and Nataluk E. Neural input regulates tissue NGF and growth of the adult rat urinary bladder. J Auton Nerv Syst 49: 147–158, 1994.[CrossRef][Web of Science][Medline]
  53. Valentino RJ, Chen S, Zhu Y, and Aston-Jones G. Evidence for divergent projections to the brain noradrenergic system and the spinal parasympathetic system from Barrington's nucleus. Brain Res 732: 1–15, 1996.[CrossRef][Web of Science][Medline]
  54. Valentino RJ, Pavcovich LA, and Hirata H. Evidence for corticotropin-releasing hormone projections from Barrington's nucleus to the periaqueductal gray and dorsal motor nucleus of the vagus in the rat. J Comp Neurol 363: 402–422, 1995.[CrossRef][Web of Science][Medline]
  55. Vincent SR and Satoh K. Corticotropin-releasing factor (CRF) immunoreactivity in the dorsolateral pontine tegmentum: further studies on the micturition reflex system. Brain Res 308: 387–391, 1984.[CrossRef][Web of Science][Medline]
  56. Vincent SR and Satoh K. Corticotropin-releasing factor (CRF) immunoreactivity in the dorsolateral pontine tegmentum: further studies on the micturition reflex system. Brain Res 308: 387–391, 1984.[CrossRef][Web of Science][Medline]
  57. Vizzard MA. Alterations in neuropeptide expression in lumbosacral bladder pathways following chronic cystitis. J Chem Neuroanat 21: 125–138, 2001.[CrossRef][Web of Science][Medline]
  58. Vizzard MA. Alterations in spinal Fos protein expression induced by bladder stimulation followng cystitis. Am J Physiol Regul Integr Comp Physiol 278: R1027–R1039, 2000.[Abstract/Free Full Text]
  59. Vizzard MA. Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction. Exp Neurol 161: 273–284, 2000.[CrossRef][Web of Science][Medline]
  60. Vizzard MA. Increased expression of neuronal nitric oxide synthase in bladder afferent and spinal neurons following spinal cord injury. Dev Neurosci 19: 232–246, 1997.[Web of Science][Medline]
  61. Vizzard MA. Up-regulation of pituitary adenylate cyclase-activating polypeptide in urinary bladder pathways after chronic cystitis. J Comp Neurol 420: 335–348, 2000.[CrossRef][Web of Science][Medline]
  62. Vizzard MA and Boyle MM. Increased expression of growth-associated protein (GAP-43) in lower urinary tract pathways following cyclophosphamide (CYP)-induced cystitis. Brain Res 844: 174–187, 1999.[CrossRef][Web of Science][Medline]
  63. Vizzard MA and de Groat WC. Increased expression of neuronal nitric oxide synthase (NOS) in bladder afferent pathways following chronic bladder irritation. J Comp Neurol 370: 191–202, 1996.[CrossRef][Web of Science][Medline]
  64. Vizzard MA, Erdman SL, and de Groat WC. Increased expression of neuronal nitric oxide synthase (NOS) in visceral neurons after nerve injury. J Neurosci 15: 4033–4045, 1995.[Abstract]
  65. Watson NA and Notley RG. Urological complications of cyclophosphamide (Abstract). Br J Urol 45: 606, 1973.[Medline]
  66. Yoshimura N and de Groat WC. Increased excitability of afferent neurons innervating rat urinary bladder following chronic bladder inflammation. J Neurosci 19: 4644–4653, 1999.[Abstract/Free Full Text]
  67. Yuridullah R, Corrow KA, Malley SE, and Vizzard MA. Expression of fractalkine and fractalkine receptor in urinary bladder after cyclophosphamide (CYP)-induced cystitis. Auton Neurosci Basic Clin 126–127: 380–389, 2006.[CrossRef]
  68. Zvarova K and Vizzard MA. Changes in galanin-immunoreactivity in rat micturition reflex pathways after cyclophosphamide (CYP)-induced cystitis. Cell Tissue Res 324: 213–224, 2006.[CrossRef][Web of Science][Medline]
  69. Zvarova K and Vizzard MA. Distribution and fate of cocaine- and amphetamine-regulated transcript peptide (CARTp)-expressing cells in rat urinary bladder: a developmental study. J Comp Neurol 489: 501–517, 2005.[CrossRef][Web of Science][Medline]
  70. Zvarova K and Vizzard MA. Ontogeny of cocaine-and amphetamine-regulated transcript peptide (CARTp) in urinary bladder and lumbosacral spinal cord of neonatal rat (Abstract). Urothel Cell Physiol Normal Dis States 58, 2005.



This article has been cited by other articles:


Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
S. K. Wood, M. A. Baez, S. Bhatnagar, and R. J. Valentino
Social stress-induced bladder dysfunction: potential role of corticotropin-releasing factor
Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2009; 296(5): R1671 - R1678.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
B. P. Cheppudira, B. M. Girard, S. E. Malley, K. C. Schutz, V. May, and M. A. Vizzard
Upregulation of vascular endothelial growth factor isoform VEGF-164 and receptors (VEGFR-2, Npn-1, and Npn-2) in rats with cyclophosphamide-induced cystitis
Am J Physiol Renal Physiol, September 1, 2008; 295(3): F826 - F836.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. B. Klinger, A. Dattilio, and M. A. Vizzard
Expression of cyclooxygenase-2 in urinary bladder in rats with cyclophosphamide-induced cystitis
Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2007; 293(2): R677 - R685.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
K. A. Corrow and M. A. Vizzard
Phosphorylation of extracellular signal-regulated kinases in urinary bladder in rats with cyclophosphamide-induced cystitis
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R125 - R134.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. Million, L. Wang, M. P. Stenzel-Poore, S. C. Coste, P. Q. Yuan, C. Lamy, J. Rivier, T. Buffington, and Y. Tache
Enhanced pelvic responses to stressors in female CRF-overexpressing mice
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2007; 292(4): R1429 - R1438.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
291/3/R692    most recent
00086.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LaBerge, J.
Right arrow Articles by Vizzard, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LaBerge, J.
Right arrow Articles by Vizzard, M. A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.